Headlines about Jounce Therapeutics (NASDAQ:JNCE) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jounce Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.6102116606814 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities research analysts recently issued reports on JNCE shares. Robert W. Baird reissued a “buy” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a report on Friday, November 10th. JPMorgan Chase & Co. set a $28.00 target price on shares of Jounce Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, Zacks Investment Research raised shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $24.00.
Shares of Jounce Therapeutics (NASDAQ JNCE) opened at $16.37 on Friday. The stock has a market cap of $495.62 and a P/E ratio of -96.29. Jounce Therapeutics has a fifty-two week low of $11.05 and a fifty-two week high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. The company had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. analysts anticipate that Jounce Therapeutics will post -0.86 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/13/jounce-therapeutics-jnce-earns-daily-media-impact-rating-of-0-09.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.